CNS Lymphoma Clinical Trial
Official title:
A Phase 1b/2, Open-label Dose Escalation With Expansion Study of GB5121 in Adult Patients With Relapsed/Refractory Primary or Secondary Central Nervous System Lymphoma or Primary Vitreoretinal Lymphoma, With a Phase 2 Open-label Single Dose Level Study of GB5121 in Adult Patients With Relapsed/ Refractory Primary Central Nervous System Lymphoma
The STAR CNS trial is a 3-part study, comprising a phase 1b dose escalation, dose expansion, and a phase 2, to assess the safety, tolerability, dose-limiting toxicity(ies), maximum tolerated dose, and/or optimal biological dose, determine the recommended phase 2 dose, preliminary anti-tumor activity and efficacy of the recommended phase 2 dose of GB5121.
Note: The Phase 1b dose expansion and Phase 2 parts of the study were not initiated. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05117814 -
Zanubrutinib Monotherapy in Relapsed/Refractory Central Nervous System Lymphoma
|
N/A | |
| Terminated |
NCT05222269 -
[68Ga]Ga-PentixaFor PET Imaging in CNS Lymphoma Patients
|
Phase 2 | |
| Recruiting |
NCT06132737 -
[90Y]Y-PTT Endoradiotherapy in CNS Lymphoma Patients
|
Phase 1/Phase 2 | |
| Completed |
NCT01319591 -
Comparison of Creatinine Clearance Calculation for Estimation of GFR in Patients Receiving HD Methotrexate
|
||
| Recruiting |
NCT06322342 -
Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent
|
Phase 2 | |
| Recruiting |
NCT05351593 -
Tafasitamab Plus Lenalidomide in Relapsed CNS Lymphoma
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT05828628 -
CLIMB: CNS Lymphoma Imaging and Molecular Biomarkers Study
|
||
| Completed |
NCT01182415 -
High Dose Chemotherapy and Stem Cell Transplant for Non-Hodgkin's Lymphoma or Central Nervous System (CNS) Lymphoma
|
Phase 2 | |
| Not yet recruiting |
NCT06343311 -
T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04841434 -
A Phase I/II Study to Investigate the Use of VORAXAZE™ as Intended Intervention in Patients With CNSL
|
Phase 1/Phase 2 | |
| Completed |
NCT01083342 -
High-Dose (HD) Methotrexate (MTX) Induction Chemotherapy Followed by Alternative HD MTX-based and HD Cytarabine-based Combination Consolidation Chemotherapy for Newly Diagnosed Primary CNS Lymphoma; CISL 10-01 Study
|
Phase 2 | |
| Completed |
NCT05293990 -
Usefulness of Gadovist-enhanced FLAIR Imaging
|
N/A | |
| Completed |
NCT00596154 -
Rituximab, Methotrexate, Procarbazine and Vincristine Followed by High-dose Chemotherapy With Autologous Stem-cell Rescue in Newly-diagnosed Primary CNS Lymphoma
|
Phase 2 | |
| Recruiting |
NCT05926427 -
Orelabrutinib Combined With Rituximab and Chemotherapy for Relapsed/Refractory B-Cell Lymphoma Patients With Central Nervous System Involvement
|
Phase 2 |